Abstract
Senegal is building a vaccine plant to create local supply of COVID-19 vaccines in Africa. Construction of the plant, which will be run by the Institut Pasteur in Dakar, is being supported by grants totaling nearly $8 million from European and American entities. The facility is expected to produce 25 million doses by the end of 2022. Separately, under a $500 million deal with the Moroccan government, the Swedish contract manufacturing firm Recipharm plans to build a plant in Morocco for the filling and finishing of vaccines and other therapeutics.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
